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Abstract: Procedures for risk assessment of chemical mixtures, combined and cumulative 
exposures are under development, but the scientific database needs considerable expansion. 
In particular, there is a lack of knowledge on how to monitor effects of complex exposures, 
and  there  are  few  reviews  on  biomonitoring  complex  exposures.  In  this  review  we 
summarize  articles  in  which  biomonitoring  techniques  have  been  developed  and  used. 
Most  examples  describe  techniques  for  biomonitoring  effects  which  may  detect  early 
changes induced by many chemical stressors and which have the potential to accelerate 
data  gathering.  Some  emphasis  is  put  on  endocrine  disrupters  acting  via  epigenetic 
mechanisms and on carcinogens. Solid evidence shows that these groups of chemicals can 
interact and even produce synergistic effects. They may act during sensitive time windows 
and biomonitoring their effects in epidemiological studies is a challenging task. 
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1. General Introduction  
Humans are subjected to a range of chemical exposures from the environment. Chemicals in air, 
water, soil and food, occupational exposures and lifestyle factors, all contribute to a complex exposure 
situation in our daily life. It has long been known that toxicity can be modified by simultaneous or 
sequential exposure to multiple agents in the environment. For some combined or mixed exposures the 
health effects may increase more than what would be expected from simply adding the effects of the 
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individual components, therefore there is a concern that several less studied complex exposures may 
have a large impact on our health as a result of combined or mixed effects.  
The  development  and  improvement  of  risk  assessment  procedures  for  combined  and  mixed 
exposures is an issue of many authorities world-wide, with on-going activities in e.g., WHO, USA and 
the European Union. The US Environmental Protection Agency published their first guideline on risk 
assessment of chemical mixtures in 1986, which was subsequently supplemented in 2000 [1,2]. Other 
activities towards a cumulative risk assessment approach are currently in progress [3]. Within the 
WHO,  the  International  Programme  on  Chemical  Safety  (IPCS)  Harmonisation  Project  currently 
develop a framework for risk assessment of combined exposure to multiple chemicals [4]. Recently, 
the Council of the European Union emphasized the need to consider combined and mixed exposures of 
chemicals in future risk assessments, and to further develop legislation, methodology, and to support 
research within this area [5].  
The need to consider a greater range of factors contributing to potential health effects of combined 
exposures makes the risk assessment process more complex compared to the assessment of single 
chemicals.  For  example,  an  increased  understanding  and  knowledge  about  the  individual  agents, 
uptake, metabolism, excretion and mechanisms/modes of action in different tissues and cells as well as 
temporal factors are needed for evaluating health risks of combined and mixed exposures. Even though 
there  has  been  recent  progress  within  this  area  of  research,  the  development  of  risk  assessment 
approaches for combined exposures is still hampered by lack of data. Techniques and methods need to 
be further developed to fill data gaps and increase the knowledge on harmful exposure combinations. 
In  a  recent  review  by  Manno  et  al.  biomonitoring  is  defined  as  ―the  repeated,  controlled 
measurement of chemical or biological markers in fluids, tissues or other accessible samples from 
subjects exposed or exposed in the past or to be exposed to chemical, physical or biological risk 
factors in the workplace and/or the general environment‖ [6]. Biomonitoring can be used to discover 
exposures to chemicals that may cause harm to human health. Biomarker data is often critical for 
chemical risk assessment and we found that biomarker information of combined or mixed exposure is 
a particular weak point in risk assessment.  
In this review, we will describe aspects of the problem posed by biomonitoring combined or mixed 
exposures to toxicants in humans. We will present examples showing how combined exposures have 
been biomonitored. Literature searches indicate that some areas have been more frequently covered 
than other areas, and we hope this will be reflected by our examples. The examples have been selected 
to illustrate biomonitoring of exposure and biomonitoring of effects at an organ level and at a cellular 
or  subcellular  level.  Chemical  carcinogenesis  and  endocrine  disruptions  are  two  areas  frequently 
implicated in combined actions and additional examples have been taken from these areas of research. 
We will end this review by discussing future developments expected in this field. 
2. Mixtures 
A mixture is defined as the combination of two or more environmental agents [7]. Mixtures can be 
categorized  in  many  ways,  e.g.,  as  being  simple  or  complex  [8].  Simple  mixtures  contain  a  
well-defined number of components, in contrast to complex mixtures. Examples of complex mixtures 
found in our environment are diesel exhaust, cigarette smoke, creosote, and asphalt fumes. For most Int. J. Environ. Res. Public Health 2011, 8           
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complex mixtures, the exact composition is usually not fully characterized. Some mixtures can contain 
hundreds of chemicals and may vary with the site of origin and the exposure situation. A mixture can 
be intentionally produced, generated or could arise coincidentally [9]. The generated and coincidental 
mixtures created in our environment are probably countless and how these impact on human health are 
largely unknown. 
There are two main principles describing how individual chemicals in a mixture affect one another: 
the  concept  of  additivity  and  interaction.  Additivity  assumes  that  chemicals  act  by  the  same  or 
different modes of action, which results in dose or effect addition. Interaction assumes that individual 
chemicals affect toxicity of one another, either by synergism or antagonism (more or less than an 
additive  effect)  [10].  Examples  of  interactions  are  agent-to-agent  interactions,  toxicokinetic  and 
toxicodynamic interactions [7,11-13]. For both the models described above there are mathematically 
based methods used to predict toxicity of mixtures. However, toxicity is not always simple to predict 
for complex mixtures. Modes of actions for some chemicals may be unknown and interacting effects 
may differ depending on dose and dose ratio [14]. Depending on the availability of data, different 
strategies for assessing the effects and risks of mixtures or combined exposures are employed for risk 
assessment. For example, the risk could be assessed using data of the mixture in question (whole-
mixture approach), using data of a similar mixture or of individual chemicals (and employing the 
concept which best applies to the particular mixture) [2,15]. This seemingly simple way to categorize 
interactions is complicated by the fact that e.g., single carcinogens or endocrine disrupters may act in 
separate  time  windows  to  synergize  or  antagonize  their  effects  e.g.,  over  a  lifetime.  Well-studied 
interactions of this type are those between so called tumour initiators and promoters. More recent 
examples include similar types of interactions between endocrine disrupters and carcinogens [16].  
3. Biomarkers of Exposure, Effects, and Susceptibility 
Biomarkers used in human health studies are typically divided into three classes; biomarkers of 
exposure, effect and susceptibility. Biomarkers of exposure involve measurements of parent compound, 
metabolites or DNA- or protein adducts and reflect internal doses, the biologically effective dose or 
target dose. Biomarkers of effects could be changes on a cellular level, such as altered expression of 
metabolic enzymes but could also include markers for early pathological changes in complex disease 
developments,  such  as  mutations  and  preneoplastic  lesions.  Sometimes  the  classification  is 
overlapping, e.g., DNA adducts could be used as biomarkers of exposure but may also imply an effect 
[17]. Biomarkers of susceptibility indicate an often constitutive ability of an individual to respond to  
specific exposures.  
Biomarkers of exposure are preferably specific for the chemicals of exposure, while biomarkers of 
effect often are unspecific for the agent in question [18]. This simple notion suggests that biomarkers 
of effect should have the greater potential to reflect complex exposures and should also have the 
ability to include aggregated and sequential exposures over time. Another comment is that the use of 
biomarkers of effect in studies of complex exposures could help to identify both the active components 
of the mixtures/combined exposure as well as the consequences of specific mixture exposures. For 
example, it has been convincingly shown that work as a painter is associated with increased risk of 
cancer. However, the specific carcinogenic agent or agents have not been characterized and further Int. J. Environ. Res. Public Health 2011, 8           
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studies  are  needed  for  cancer  prevention  [19].  These  include  the  biomonitoring  of  exposure  to 
individual agents and the biomonitoring of early effects for identifying causative agents, or rather 
mixtures of agents. 
An example of a biomarker of exposure that has been used in many studies on complex mixtures of 
polycyclic aromatic hydrocarbons (PAHs) is the excretion of 1-hydroxypyrene in urine [13]. PAHs 
belong to a group of chemicals formed as complex mixtures in many combustion processes. Many 
PAHs have been shown to be carcinogenic in animals via a genotoxic mode of action and are of great 
toxicological  concern.  Benzo(a)pyrene  is  perhaps  the  most  well  studied  PAH  and  was  recently 
classified as a human carcinogen by IARC [20]. Detecting and quantifying PAHs in air samples is a 
challenging task, and benzo(a)pyrene is often used as a marker for all PAHs. This approach is far from 
ideal as the composition may vary with the sources and with time since formation. Moreover, there are 
several other even more potent carcinogens than benzo(a)pyrene found in many PAH mixtures, one 
example is dibenzo(a,l)pyrene. It was recently shown that dibenzo(a,l)pyrene contributed more than 
any other PAH to the carcinogenic potency of particles in ambient Stockholm air [21]. In an effort to 
reduce  these  problems,  many  studies  have  employed  1-hydroxypyrene  excretion  in  urine  as  a 
biomarker for PAH exposure. Pyrene is one of the most abundant hydrocarbons in PAH mixtures and 
is considered a more sensitive biomarker than benzo(a)pyrene. Biomonitoring of 1-hydroxypyrene in 
urine has e.g., been used in studies of people working in aluminium smelter plants and in workers 
exposed to asphalt fumes or creosote [22-24]. Recently metabolites of another PAH, phenanthrene, has 
been used as a biomarker for occupational exposure of PAH [25]. A method for measuring several 
volatile organic compounds (VOCs) in alveolar air from exposed workers was recently suggested [26]. 
This  method  allowed  biomonitoring  up  to  26  single  VOCs  and  this  method  could  be  used  for 
measuring biomarkers of exposure in workplaces with complex VOC exposure. 
DNA  adducts  are  often  considered  biomarkers  of  exposure,  whereas  gene  mutations  and 
chromosomal alterations are often considered biomarkers of early biological effects in carcinogenic 
processes  [27].  Other  examples  of  biomarkers  of  effect  of  relevance  for  complex  mixtures  are 
measurements of changes in biological systems, e.g., acetylcholinesterase inhibition by mixtures or 
combined exposure to organophosphate pesticides [28].  
Proteomics and toxicogenomics techniques could help to discover new biomarkers of effect. For 
example, altered gene expression patterns were studied in cells exposed to an urban dust particulate 
complex mixture, and these data may be used to develop new techniques for biomonitoring effects of 
urban  dust.  In  further  support  for  the  potential  importance  of  this  method  for  biomonitoring  of 
mixtures or combined exposures, global analyses of gene expression data demonstrated changes in 
more than 40 RNA transcripts in response to the mixed exposure [29]. 
Biomarkers  of  susceptibility  may  include  polymorphisms  of  specific  genes  associated  with  the 
metabolism of toxic material in the body [28]. Inherited genetic differences in metabolism can have an 
effect on a population level, rather than on an individual level, and may result in different effects for a 
given exposure [28]. Thus, many single nucleotide polymorphisms (SNPs) result in altered expression 
or activity of the gene product and may modulate the response to a toxicant. Such biomarkers can also 
involve  enzymes  responsible  for  DNA  repair  and  tumour  suppressor  proteins.  These  enzymes  or 
signalling proteins are of importance for the toxicity of many toxicants and may modulate the response 
to mixed or combined exposures. If a certain well-characterized SNP can be shown to influence the Int. J. Environ. Res. Public Health 2011, 8           
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response to a poorly defined complex mixture, it might give information regarding which components 
of a complex mixture are active.  
4. The Biomonitoring Matrix 
Biomarkers can be measured in exhaled air, blood, urine and in tissue samples. The actual target 
organ or cell is usually not available for measurements and biomarkers of exposure are thus often 
surrogate  measures  of  doses  or  effects  at  the  target.  The  ideal  biomarker  has  been  described  as 
chemical-specific,  detectable  at  low  (trace)  levels,  available  using  non-invasive  techniques, 
inexpensive to analyse and quantitatively related to prior exposures [30]. Thus, for biomonitoring 
purposes,  biological  materials  should  be  easily  accessible  in  sufficient  amounts  under  routine 
conditions and without unacceptable discomfort and health risk for the individual. For these reasons 
blood and urine are most commonly used and cells in blood may provide surrogate endpoints for 
effects in internal organs [31]. Hair, teeth and nails have also been used for biomonitoring, but the 
knowledge of these media and biomarkers is limited [32]. New non-invasive methods, such as saliva 
and breath, are under development [33,34]. Sampling of exfoliated buccal cells for biomonitoring is 
another  non-invasive  technique  employed,  but  these  assays  may  require  further  improvement  and 
validation [35]. The choice of matrix may also influence the exposure time a marker will reflect. 
Levels of chemicals in blood usually reflect a short time period of exposure (a few hours or days) [17] 
whereas adduct levels in blood proteins may reflect a much longer time of exposure. 
5. Target Organs 
5.1. Kidney 
Heavy metals exhibit very long biological half-lives and are toxic at very low doses, and there are 
numerous studies on combined effects of metals. Among many organs affected by metals, the kidney is 
one important target organ, which relates to the kidney’s ability to reabsorb and accumulate divalent 
metals. The combined exposure to metals such as lead, cadmium and arsenic may lead to both additive 
and synergistic effects [36], but also antagonistic effects have been described. Traditional endpoints of 
toxicity have been morphological changes and biochemical markers for kidney toxicity and these have 
been shown useful at high dose exposures. Other biomarkers such as oxidative stress, altered heme 
biosynthesis and increases in different stress proteins could be more suitable for evaluating toxicity at 
lower doses [36].  
In kidney, combination exposure of metals such as lead, cadmium and arsenic results in increased 
urinary  excretion  of  porphyrins  and  this  have  been  suggested  as  a  good  biomarker  for  the  
combined  or  mixed  exposure  of  metals  [17,36].  The  expression  of  metal-binding  proteins  and  
methyl-transferase-mediated metabolic pathways may play important roles in mediating the outcomes 
of  combined  or  mixed  exposure  to  metals  and  can  thus  be  regarded  as  good  biomarkers  [36]. 
Furthermore,  metallothioneins  have  also  been  suggested  as useful biomarkers for studying kidney 
toxicity caused by exposure to metal mixtures. Induction of metallothioneins could affect other metals 
by altering toxicokinetic and toxicodynamic processes. A recent example concerns urinary levels of 
beta-2-microglobulin and N-acetyl-β-D-glucosaminidase. These biomarkers of renal tubular damage Int. J. Environ. Res. Public Health 2011, 8           
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were  measured  in  a  population  in  China  exhibiting  increased  levels  of  arsenic  and  cadmium  in  
urine  [37].  Metal  exposure  gave  considerably  higher  biomarker  values  than  exposure  to  each  
metal alone. 
Urinary  excretion  of  enzymes  such  as  α-glutathione-S-transferase  has  been  found  useful  in 
biomonitoring of early changes in the proxitubular structure and function in occupationally exposed 
workers.  Exposure  to  metal  mixtures  has  also  been  shown  to  result  in  clastogenic and aneugenic 
effects in peripheral lymphocytes [36].  
Urinary  excretion  of  the  oxidative  stress  marker  8-hydroxyguanine  was  measured  in  66  
nickel-cadmium battery workers [38]. A correlation between workers having high nickel concentration 
in  urine,  high  cadmium  concentration  in  blood  and  high  levels  of  8-hydroxyguanine  in  urine  
was observed. 
5.2. Liver 
Solvents may damage liver cells and liver transaminases may be used to monitor liver damage after 
combined or mixed exposure. In a toxicity study of a chloroform trichloroethylene mixture, alanine 
aminotransferase  (ALT)  activity  in  rat  blood  plasma  was  measured  and  combined  with  a 
histopathological assessment. In this case data suggested that the two substances had an antagonistic 
effect [39]. 
In a study of workers exposed to a mixture of solvents in car repainting shops, different biochemical 
parameters of liver function were measured, such as alkaline phosphatase (ALP), total bilirubin (TB) 
and  aspartate  aminotransferase  (AST).  These  markers  showed  significantly  higher  levels  in  the 
workers compared to a control group. Furthermore, the authors found that serum bile acids were the 
most sensitive markers for detecting liver injury, suggesting that serum bile acids could be a valuable 
biomarker of hepatotoxicity caused by organic solvents [40]. The cumulative (over time) exposure of 
solvents and liver biomarkers was evaluated in 29 exposed workers. The study reports that higher liver 
enzymes activities of AST and ALT in blood related to exposure during the past 5 years, while higher 
levels of triglycerides reflected the total lifetime cumulative solvent exposure [41]. 
5.3. Lung 
Many inhaled toxicants affect the lungs and the Clara cell protein CC16 in serum has been used as a 
biomarker of lung effects in studies on complex occupational exposures [42,43]. In addition, more 
general markers of genotoxicity such as bulky DNA adducts, oxidative stress markers, and mutations 
in surrogate tissues or cells have been used for measuring effects of the combined exposure to air 
pollutants [44,45]. 
5.4. Nervous System 
The complexity of the nervous system has hindered the development of biomonitoring strategies for 
chemicals  affecting  this  organ.  Metals,  solvents  and  pesticides  have  been  measured  as  parent 
compounds or as metabolites in blood, urine and hair [46]. In particular, biomarkers of effect have 
been difficult to establish, which may relate to the facts that even very subtle alterations in small Int. J. Environ. Res. Public Health 2011, 8           
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groups of cells can have clinically detectable effects. One example of biomonitoring the effects of 
relevance to the nervous system is measurements of acetylcholinesterase activity in red blood cells 
following complex exposure to organophosphorus insecticides [46]. 
5.5. Blood 
Blood is commonly used for biomonitoring purposes. Levels of chemicals and/or their metabolites 
can  be  measured  in blood.  Many  other types of biomarkers like micronuclei;  acetylcholinesterase 
activity etc. can be measured in blood. White blood cell counts, or myelosuppression, may be used to 
monitor drug effects in clinical settings in cancer patients exposed to cocktails of chemotherapeutic 
drugs [47]. 
6. Biomonitoring a Joint Mode of Action: Oxidative Stress 
Low levels of oxidative stress may reflect normal metabolism, but oxidative stress is also a common 
pathological process that might have a role in the development of many diseases. Inflammation and 
oxidative stress are involved in chronic diseases such as atherosclerosis and tissue fibroses, and are 
seen in many lung diseases. Another disease commonly associated with oxidative stress is cancer. 
Many metals including arsenic and selenium as well as many xenobiotics, such as dioxins, PCBs, 
PAHs and other carcinogens have been shown to cause oxidative stress. This means that monitoring 
oxidative  stress  could  be  an  informative  way  to  study  interactions  between  numerous  toxicants. 
However, it should be kept in mind that oxidative stress sometimes is an important causative factor 
and sometimes only a bystander in an agent’s, or a mixture’s, toxicological profile.  
Endogenous DNA adducts that result from oxidative stress are always present in genomic DNA and 
may be generated as artefacts during sample preparation. The non-zero background causes uncertainty 
when risks are extrapolated from hazardous chemicals that produce oxidative stress that is important 
for toxicity and/or carcinogenicity. Base oxidation is one of the most frequent insults to DNA and 
commonly used biomonitoring markers are end products of oxidative DNA damage. These markers 
include e.g., 8-oxo-7,8-dihydro-2′-deoxyguanisine and malondialdehyde-dG adducts [48]. 
Markers of oxidative stress have been demonstrated to be sensitive effect biomarkers both at high 
and low doses of combined metal exposures. A common cellular target for single metal exposure is the 
mitochondria, which is also the major intracellular source of reactive oxygen species. Oxidative stress 
caused by mixtures of metals may lead to an increased malondialdehyde (a breakdown product of 
peroxidised  fatty  acids)  excretion  in  urine.  Induction  of  8-hydroxy-2’-deoxy-guanosine  and  an  
up-regulated  expression  of  antioxidant  enzymes,  such  as  superoxide  dismutase  and  glutathione 
peroxidases, has also been shown after combined exposures [36]. 
When investigating the role of oxidative stress in the pathogenesis of disease, and when using 
oxidative  stress  as  endpoint,  a  panel  of  biomarkers,  specific  for  the  different  types  of  oxidative  
stress-induced damages, might be advantageous [49].  
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7. Biomarkers and Cancer 
The  field  of  biomarkers  reflecting  carcinogen  exposure  and  effects  is  well  studied.  A  possible 
reason for this interest is the knowledge that cancer development takes many years and that there is a 
need for early markers of effect. A latency of 10–40 years between first exposure and diagnosis is 
commonly anticipated. In addition, interactions between different types of carcinogens, e.g., initiators 
and promoters and their interactions over time have been well characterised in animal models. These 
circumstances  have  led  to  the  development  of  many  biomarkers  of  exposure  and  effect  [50]  and 
fortunately,  many  of  the  effect  biomarkers  could  be  useful  for  monitoring  both  combined  and  
mixed exposures.  
As mentioned above, analysis of 1-hydroxypyrene in urine has been used to monitor exposure of 
PAHs. It is important to note that many endpoints used in studies concerning carcinogens are not 
compound  specific  but  are  targets  for  many  chemicals  or  groups  of  chemicals.  Thus,  they  are 
sometimes used for biomonitoring exposures to mixtures or for biomonitoring aggregated effects.  
Genotoxic xenobiotics cause direct DNA damage, which can be biomonitored as a single endpoint, 
although the type of DNA damage may vary. It is important, however, to keep in mind that not all 
DNA adducts are equally prone to cause mutations. The mutagenic capacity may depend on e.g., type 
of adduct, the capacity for DNA repair and cell type. Furthermore, DNA adducts are also formed 
endogenously, from normal metabolic or dietary components [27]. Endpoints useful for biomonitoring 
of complex mixtures include the so called comet assay which measure DNA strand breaks. Surrogate 
target  cells  include  samples  of  blood  lymphocytes  or  buccal  leucocytes.  The  buccal  leucocytes 
approach has been used for biomonitoring asphalt workers exposed to the complex mixture in asphalt 
fumes [51]. 
Measuring urine mutagenicity by employing salmonella tests for mutagenicity, so called Ames tests, 
should integrate the effects of all mutagenic compounds excreted in urine. A group of 29 workers 
studying or teaching in organic chemistry and exposed to organic solvents were tested for their urine 
mutagenicity.  Mutagenicity  was  assayed  with  the  salmonella  plus  microsome  assay.  Compared  to 
controls, significant differences in mutagenic activity of urine samples were detected [52]. The authors 
suggest that this effect was due to the combined solvent exposure, but the sources of mutagenicity 
were  not  studied.  Another  study,  employing  several  biomonitoring  endpoints  were  selected  to 
demonstrate effects of complex polluting mixtures, analysed blood from children in Silesia in Polen. 
Pollutants were derived from mining, smelting activities, heavy industry with coal-based power, steel 
and coke plants, heavy automobile traffic and coal for domestic heating. Among other findings, a 
correlation  between  PAH  exposure,  measured  as  1-hydroxypyrene  in  urine,  correlated  with  sister 
chromatid  exchanges  in  peripheral  lymphocytes  [53].  Previously,  adults  living  in  the  same 
geographical area were investigated in a seminal study in the field of biomonitoring [54]. A partially 
different  battery  of  biomonitoring  endpoints  reflecting  precarcinogenic  effects  were  related  to 
residency in this area, and the highest levels were often recorded in samples taken during winter. For 
example, overexpression of the ras oncogene in plasma was found in the samples taken during winter, 
suggesting a strong influence of complex exposure caused by domestic coal heating.  
Mutations as biomarkers of cancer represent more specific endpoints than DNA damage. Mutations 
can occur in reporter genes, such as HPRT (i.e., genes not related to cancer development, but used as Int. J. Environ. Res. Public Health 2011, 8           
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surrogates because they are relatively easily evaluated), or more specifically, in oncogenes or tumour 
suppressor genes. The mutation spectra in the tumour suppressor p53 have been extensively studied. 
Some mutations have been claimed to reflect carcinogen specificity, such as the codon 249 mutations 
caused by aflatoxin exposure [55]. Many other ―hot spot‖ mutations in the p53 gene have not been 
associated  with  single  carcinogenic  compounds  but  may  reflect  effects  of  many  xenobiotics,  and 
should be suitable for biomonitoring mixtures. Other mutations have been associated with oxidative 
stress and may thus reflect endogenous oxidative stress induced e.g., by inflammation or by oxidative 
stress inducing xenobiotics or viruses [56]. Interestingly, the detection of mutated p53 protein in blood 
has been correlated to aflatoxin exposure [56], but may also reflect complex carcinogenic exposures. 
Other  biomarkers  of  early  effects  are  chromosome  aberrations,  micronuclei  and  aneuploidy.  A 
recent example is the evaluation of markers for genotoxicity in 30 workers exposed to low doses of 
antineoplastic drugs and 57 workers exposed to low doses of PAHs (including 41 airport workers and 
16  paving  workers)  [57].  Micronucleus  and  comet  assays  were  performed  on  lymphocytes  and 
exfoliated buccal cells. The micronucleus assays on buccal cells showed significantly higher values in 
workers exposed to antineoplastic drugs as compared to controls. In addition, buccal cells proved to be 
the best target cells for the comet assay when the biological effects of PAH mixtures were evaluated; a 
significant difference between PAH-exposed workers and their respective control group was found for 
tail moment in the comet assay [57]. It has been suggested that increased levels of micronuclei in 
blood could be used to predict cancer risk, especially for urogenital and gastro-intestinal cancers [58]. 
An example of effect biomarkers related to carcinogens was shown in a recent study where levels of 
chromosomal damage endpoints such as nucleoplasmic bridges and nuclear buds were significantly 
higher in workers exposed to PAHs compared to controls. The authors suggested that these endpoints 
were sensitive and reliable biomarkers for genetic damage induced by PAHs [59].  
We  have  found  no  literature  on  general  biomarkers  suitable  for  non-mutagenic  carcinogens. 
Enzyme  induction,  cell  proliferation,  inhibition  of  gap  junction  intracellular  communication  and 
modulation of apoptosis are examples of common modes of action for these types of carcinogens [60]. 
These endpoints have been mostly studied in animal and cell experiments. It can be added that a large 
array of signalling molecules are critical for non-mutagenic carcinogenic effects and that genomic and 
proteomic approaches should be well suited for the future development of this area of research. Such 
endpoints should help to identify novel potential biomarkers for non-mutagenic carcinogenic effects of 
chemicals in humans [17]. 
8. Biomarkers and Endocrine Disrupting Chemicals 
Recent studies indicate that endocrine disrupting chemicals may interact in complex ways (for a 
comprehensive  and  recent  overview  see  [61]).  In  particular  endocrine  disrupting  chemicals  may 
interact over time, in a way similar to that of many carcinogens. The endocrine disrupting mode of 
action has caused concern, especially as even low exposure during foetal or early life periods might be 
involved [62]. This characteristic will certainly complicate the detection of harmful interactions in 
epidemiological studies and there is a great need for reliable biomarkers of effect. Endocrine disrupters 
are  mainly  assumed  to  act  via  epigenetic  effects  and  prospects  for  epigenetic  epidemiology  have 
recently been reviewed [63]. This paper summarizes environmental risk factors, exposure scenarios Int. J. Environ. Res. Public Health 2011, 8           
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over  time  and  methodology.  Unfortunately,  published  biomonitoring  data  on  endocrine  disrupting 
chemicals mainly focus on agent-specific exposure markers, not on effect markers.  
Phthalates  are  ubiquitous  xenobiotics  found  in  many  plastic  products,  cosmetics  etc.  Many 
phthalates  have  shown  endocrine  disrupting  and  anti-androgenic  properties  in  animal  studies,  but 
usually these phthalates have been investigated one at a time. However, in a recent study on newborn 
boys, their mothers were monitored during pregnancy for prenatal phthalate exposure, and several 
phthalates  derived  from  domestic  and  life  style  related  exposures  were  biomonitored  [64].  The 
ubiquitous occurrence of phthalates suggests that analysing metabolites in urine is a way to avoid 
contamination  problems.  A  combined  phthalate  exposure  index  was  defined  for  each  pregnant 
woman/mother and it was found that this index of combined phthalate exposure correlated to the 
anogenital  distance  (AGD).  A  reduction  of  the  AGD  has  previously  been  associated  with  anti-
androgen effects of hormonal disruption in animal studies. This study suggests that the exposure of 
pregnant  women  to  phthalates  in  the  daily  environment  may  have  effects  on  foetal  development. 
However,  additional  studies  showing  similar  effects  of  similar  exposures  are  needed  for  more 
definitive conclusions and the effect of single phthalates versus the combined effect of all analysed 
phthalates remains to be studied. It can be noted that the index for combined exposure gave a stronger 
significance compared with the significance for any single phthalate, suggesting a major contribution 
by the combined action.  
In a later study, different matrices for biomonitoring phthalate exposure were evaluated. It was 
found  that  monitoring urinary levels  of phthalate  metabolites  was a better method for monitoring 
exposure than measuring metabolites in breast milk or in blood [65]. More comprehensive reviews on 
the biomonitoring of phthalate exposure were recently published [66,67].  
Estrogenicity caused by combined or mixed exposures could be determined by using the concept of 
―total  effective  xenoestrogenic  burden‖  (TEXB).  TEXB  may  serve  as  a  biomarker  of  endocrine 
disruption. Human specimens such as adipose tissue could be used to determine the combined or 
mixed  effect  of  xenoestrogens  using  the  estrogen  screen  (E-screen)  bioassay.  In  this  method, 
xenoestrogens  are  separated  from  endogenous  hormones  by  HPLC.  Fractions  are  then  tested  for 
estrogenic activity using the E-screen; the activity in MCF-7 human breast cancer cells treated with 
oestrogen (as a positive control) is compared with the activity in tissue extracts. The effect on cell 
proliferation  is  then  evaluated.  The  effective  burden  represents  the  combined  effects  of  chemical 
compounds  in  the  tissue  extract  [68].  This  procedure  has  also  been  applied  when  analysing 
xenoestrogenic extracts from human placenta [69], and was used in a case-control study. 50 newborn 
boys with cryptorchism and/or hypospadias were compared with 114 boys without malformations. 
72% of the cases and 54% of the controls had detectable xenoestrogens in their placentas and this 
difference was significant (p < 0.05) [70]. This study support the idea that TEXB measured in placenta 
extract can be used as a biomarker of exposure in studies on hormonal disruption. 
It  has  been  suggested  that  dichloroanilines  in  human  urine  can  be  used  as  common  exposure 
markers for several pesticides, including pesticides with endocrine disrupting properties [71]. In a 
recent study, the association between exposures to organophosphate compounds and serum levels of 
thyroid hormones were studied in floriculture workers (136 men). Serum increases of both TSH and 
T(4)  hormones  were  associated  with  an increase in total dimethylphosphate levels in  urine and  a Int. J. Environ. Res. Public Health 2011, 8           
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decrease in total T(3) serum level. The authors conclude that the findings support the hypothesis that 
organophosphate pesticides can act as endocrine disruptors in humans [72]. 
With the aim to shorten animal studies, effect markers for malformations have been studied in 
animals [73]. After in utero and postnatal exposure to mixtures of anti-androgens the AGD, nipple 
retention and a dysgenesis score were measured. It was found that at least the AGD at birth predicted 
later  developed  hypospadias. During  a later  rat study, the same authors used these endpoints and 
described  a  synergistic  interaction  between  four  androgen  disrupters.  Di(2-ethylhexyl)phthalate, 
vinclozolin,  prochloraz  and  finasteride  were  selected  for  the  study  as  they  act  with  differing 
mechanisms [74]. 
The hypothesis of a testicular dysgenesis syndrome (TDS) is based on several observations on early 
manifestations at birth, such as cryptorchism and hypospadias and later development of infertility and 
germ cell cancer in testes of young men [75]. A role of endocrine disrupting chemicals has been 
discussed,  and  several  associations  have  been  documented  in  humans.  As  mentioned  above  [74], 
animal studies have shown that combined exposures to low doses, incapable to induce effects of their 
own, can result in a reduced AGD [76]. It is thus feasible that future studies on testicular cancer or 
infertility  may  use  early  manifestations  of  TDS  as  effect  biomarkers  of  chemicals  causing  
endocrine disruption. 
Efforts  to  develop  markers  for  endocrine-disrupting  chemicals  involved  in  prostate  cancer 
development have been reported. It has been shown in rats that methylations of certain genes, such as 
PDE4D4, are induced by e.g., bisphenol A and estradiol very early in prostate cancer development and 
may facilitate prostate cancer development. An advantage of measuring this protein change is that it 
can be detected before the onset of histopathological changes. The authors suggest that this and other 
methylations in the genome can be used as markers for epigenetic changes induced by environmental 
endocrine disruptors [77]. This type of effect marker might be informative in epidemiological studies 
on endocrine-disrupting chemicals which include data from biopsy material. 
9. Future Perspectives 
Cancer-causing  chemicals  may  alter  gene  expression  by  epigenetic  mechanisms,  and  such 
mechanisms have the potential to become important biomarkers in future applications. Importantly, 
epigenetic changes may often be of reversible nature and detecting such early changes can not only be 
used  for  risk  assessment  purposes  but  also  benefit  both  therapeutic  as  well  as  preventive  
monitoring [78].  
For  combined  or  mixed  exposures  an  array  of  biomarkers  has  been  suggested,  where  each 
individual  biomarker  provide  some  of  the  ideal  characteristics  of  a  specific  biomarker  [28].  For 
example,  to  accurately  evaluate  inhaled  complex  mixtures,  measuring  a  panel  of  biomarkers  is 
suggested [18]. The development of newer techniques such as gene arrays and proteomics may yield 
interesting results within this field. Large number of genes can be monitored and alterations in gene 
expression after combined exposure can be analysed [17]. The best biomarker in this sense would be a 
combination of approaches at different levels of cellular organization, such as DNA, RNA and proteins 
[79]. There is also a need for development of methods that measure effects at low dose levels [17]. Int. J. Environ. Res. Public Health 2011, 8           
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The US EPA suggests that specific research is focused on using pharmacokinetic (PBPK) models to 
understand biomarker data and to estimate target tissue doses in cases where surrogate targets have 
been used. The US EPA further suggests that the biochemical and mathematical relationships among 
biomarkers, exposures, and internal dose for non-persistent chemicals needs to be evaluated. Linking 
exposure to health effects using a system biology approach is yet another future challenge [34]. 
Recent initiatives in changing toxicity testing, from being mainly based on animal tests to cell based 
techniques [80] should not only speed up the testing of old and new chemicals, but may also give 
valuable input in the field of biomonitoring. According to ―Toxicity Testing in the 21st Century: A 
Vision and  Strategy‖ [81] a key issue is to define toxicity pathways, signaling pathways that are 
perturbed by toxic chemicals. Estimates on how many such pathways that will be defined in the future 
vary from 132 to an unlimited number. Besides, this search for signaling pathways may result in the 
identification  of  molecular  ―nodes‖  in  cells  that  are  particularly  vulnerable  to  chemical  insults. 
Enormous resources are now put into high-throughput screening of chemicals in cell based models, 
and efforts are made to get proof-in-principal data showing that pathway perturbations can predict 
results from animal testing [82]. 
Ideally, alterations in a limited number of such nodes may signify key toxic events in response to 
large groups of chemicals. It can then be anticipated that alterations in such nodes may integrate 
complex signaling in several pathways. The tumour suppressor protein p53 is one of several endpoints 
that will be monitored in ongoing high-throughput studies [80], and alterations in this protein may 
reflect chemical exposures leading to DNA damage and repair. This can be induced by a large group of 
DNA-binding chemicals and by chemicals inducing oxidative stress and inflammation. Furthermore, 
p53 alterations are also induced by other stressors and may integrate e.g., DNA repair activities with 
nutritional status etc. This integration may result in cell cycle stop for DNA repair, or alternatively in 
replicative senescence or apoptosis. All three responses may have different pathological consequences 
and may affect the toxicological profile of a chemical, a chemical mixture or combined exposure.  
From this on-going process we can expect a quantity of data of more or less direct importance for 
biomonitoring. It can e.g., be expected that some of the nodes discussed above should be close to ideal 
for biomonitoring purposes of complex or mixed exposures. However, critics are worried that cell 
signaling  might  be  more  complex  than  presently  anticipated.  For  example,  the  database  PubMed 
presently lists 837 papers on crosstalk between signaling pathways, indicating a layer of complexity 
that is often overlooked. Furthermore, uncountable papers on posttranslational modifications of gene 
products further increase the complexity in delineating a cell’s signaling [83].  
Other potentially interesting targets for biomonitoring are telomeres. These DNA stretches form the 
end of chromosomes and are shortened by cell divisions, and it has been suggested that telomere 
attrition might be used for biomonitoring purposes [84]. Several papers have been published indicating 
a correlation between oxidative stress, inflammation, atherosclerosis, hypertension, chronic obstructive 
pulmonary disease, aging and telomere attrition. Chemically induced stresses may lead to these types 
of  effects  and  indeed,  smoking  has  repeatedly  been  shown  to  enhance  telomere  attrition  [85]. 
Furthermore, telomere length may also function as a marker for susceptibility [84,86,87], suggesting 
that measuring telomere attrition might be an informative marker for many types of complex chemical 
exposures.  It  was  recently  showed  that  the  telomere  length  in  peripheral  blood  leukocytes  of 
professionals  exposed  to  PAHs  [88]  or  to  traffic  pollution  [89]  was  shortened.  Inflammation  and Int. J. Environ. Res. Public Health 2011, 8           
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oxidative stress seems to be common factors underlying these effects [90]. A complicating factor is 
that telomerase activity may compensate for telomere shortening, in leucocytes [91]. 
A so far unanswered question is which cell types should be used for biomonitoring these endpoints. 
Toxicological  processes  may  of  course  take  place  in  many  parenchymal  cells  in  the  body,  not 
accessible for biomonitoring. It is thus clear that in most cases surrogate cell types such as blood 
lymphocytes have to be used. Their reliability for this purpose, as well as other indirect biomatrices, 
remains to be evaluated. 
In  parallel  with  the  development  and  increased  use  of  methods  for  human  biomonitoring,  also 
ethical questions arise that may need consideration. These issues may vary from sector to sector in 
society. Ethical issues have been discussed in several recent articles, see e.g., [6,92,93], and should be 
applicable regardless whether single, mixed or combined exposures are biomonitored.  
In conclusion, even though we have found a number of studies evaluating the use of biomarkers and 
biomonitoring for combined or mixed exposures, further development in this area is urgently needed. 
There  are  many  questions  to  answer  about  presently  used  biomarkers  and  their  relation  to  health 
effects. Future goals include the development of specific biomarkers for combined or mixed exposure 
taking advantage of the ongoing characterization of toxicity signaling pathways. 
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